Brian Stwalley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brian Stwalley has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth C. Dabrowski
Aetion, Inc. 3 Scientific Engagement New York, New York
7 shared publications - Gregory A. Vidal
Clinical Research and Breast Oncology Program, Lee S Schwartzberg Research Center, West Cancer Center and Research Institute, Memphis, Tennessee
7 shared publications - Julie Katz
Gilead Sciences, Inc. 2 Real World Evidence Oncology Foster City, California
7 shared publications - Kevin Kalinsky
Winship Cancer Institute at Emory University, Atlanta, USA
7 shared publications - Natalia Sadetsky
Gilead Sciences, Inc. 2 Real World Evidence Oncology Foster City, California
7 shared publications - Peter A. Kaufman
University of Vermont Medical Center
7 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing the definitions used for each US geographic region
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing the definitions used for each US geographic region
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A schematic diagram of patient disposition and exclusion criteria
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A schematic diagram of patient disposition and exclusion criteria
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background:Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors.Methods:A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods.Results:The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.Conclusions:We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.Impact:These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background:Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors.Methods:A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods.Results:The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.Conclusions:We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.Impact:These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing baseline demographics and disease characteristics divided by SES index
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing baseline demographics and disease characteristics divided by SES index
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Additional detail on the methodology for subgroup analyses and statistical analyses
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Additional detail on the methodology for subgroup analyses and statistical analyses
- Open Access
- 29 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (4) , 588-596
Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors. Methods: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods. Results: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed. Conclusions: We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings. Impact: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- 29 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (4) , 588-596
Open AccessSociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors. Methods: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods. Results: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed. Conclusions: We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings. Impact: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- 1 October 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (28_suppl) , 305
Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab.
305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for the treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), and the treatment paradigm has changed dramatically over the past few years. This real-world study examined treatment patterns and sequences, treatment response, safety, and survival outcomes with this novel first-line (1L) combination therapy among patients diagnosed with metastatic RCC (mRCC) in a community oncology practice setting. Methods: A retrospective analysis of the US Oncology Network’s iKnowMed medical data examined adult patients with an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognosis of intermediate- or poor-risk clear cell mRCC who received 1L NIVO+IPI between April 1, 2018, and March 31, 2020. Baseline demographic and clinical characteristics, treatment patterns, and treatment sequence were examined descriptively. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), time to treatment discontinuation (TTD), and time to treatment response (TTR) were analyzed using the Kaplan–Meier method. Treatment-related adverse events (TRAEs) and healthcare resource utilization were also analyzed. Results: A total of 193 adults with stage IV mRCC treated with 1L NIVO+IPI were identified. Median age (range) was 63 (30.0–89.0) years, 73.1% were male, 69.4% were white, 56.7% were IMDC intermediate risk, and 60.6% had a documented Eastern Cooperative Oncology Group performance status of 0 or 1. Median follow-up time (range) was 9.7 (0.1–24.7) months. Median PFS (95% CI) was 17.1 (12.6–21.2) months, and the 1-year landmark PFS rate was 58.3% (50.4–65.4). At 12 months, the OS rate (95% CI) was 75.4% (67.8–81.4). The ORR (95% CI) was 43.2% (34.6–52.1) among patients with a response assessment; the median TTR (range) was 2.8 (0.3–4.1) months and median DoR was not reached. Median TTD (95% CI) was 5.8 (4.5–7.5) months. Among the 63 (31.3%) patients who received second-line therapy, 50.8% received cabozantinib and 12.7% received pazopanib. TRAEs were reported in 47.2% of patients—the most frequently reported were fatigue (13.5%), rash (10.4%), diarrhea (6.7%), nausea (6.2%), colitis (3.6%), and pruritus (3.6%). The treatment-related hospitalization rate was 5.5% and the emergency department visit rate was 3.1%. Conclusions: This real-world study supports the clinical efficacy of 1L NIVO+IPI for patients with mRCC. Our findings also suggest that the NIVO+IPI combination was generally well tolerated in the real-world setting, with low rates of adverse events and healthcare resource utilization.
- 1 October 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (28_suppl) , 305
Real-world outcomes in patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab.
305 Background: Nivolumab plus ipilimumab (NIVO+IPI), a first-in-class combination immunotherapy, was approved by the US Food and Drug Administration in April 2018 for the treatment of intermediate- or poor-risk advanced renal cell carcinoma (RCC), and the treatment paradigm has changed dramatically over the past few years. This real-world study examined treatment patterns and sequences, treatment response, safety, and survival outcomes with this novel first-line (1L) combination therapy among patients diagnosed with metastatic RCC (mRCC) in a community oncology practice setting. Methods: A retrospective analysis of the US Oncology Network’s iKnowMed medical data examined adult patients with an International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognosis of intermediate- or poor-risk clear cell mRCC who received 1L NIVO+IPI between April 1, 2018, and March 31, 2020. Baseline demographic and clinical characteristics, treatment patterns, and treatment sequence were examined descriptively. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), time to treatment discontinuation (TTD), and time to treatment response (TTR) were analyzed using the Kaplan–Meier method. Treatment-related adverse events (TRAEs) and healthcare resource utilization were also analyzed. Results: A total of 193 adults with stage IV mRCC treated with 1L NIVO+IPI were identified. Median age (range) was 63 (30.0–89.0) years, 73.1% were male, 69.4% were white, 56.7% were IMDC intermediate risk, and 60.6% had a documented Eastern Cooperative Oncology Group performance status of 0 or 1. Median follow-up time (range) was 9.7 (0.1–24.7) months. Median PFS (95% CI) was 17.1 (12.6–21.2) months, and the 1-year landmark PFS rate was 58.3% (50.4–65.4). At 12 months, the OS rate (95% CI) was 75.4% (67.8–81.4). The ORR (95% CI) was 43.2% (34.6–52.1) among patients with a response assessment; the median TTR (range) was 2.8 (0.3–4.1) months and median DoR was not reached. Median TTD (95% CI) was 5.8 (4.5–7.5) months. Among the 63 (31.3%) patients who received second-line therapy, 50.8% received cabozantinib and 12.7% received pazopanib. TRAEs were reported in 47.2% of patients—the most frequently reported were fatigue (13.5%), rash (10.4%), diarrhea (6.7%), nausea (6.2%), colitis (3.6%), and pruritus (3.6%). The treatment-related hospitalization rate was 5.5% and the emergency department visit rate was 3.1%. Conclusions: This real-world study supports the clinical efficacy of 1L NIVO+IPI for patients with mRCC. Our findings also suggest that the NIVO+IPI combination was generally well tolerated in the real-world setting, with low rates of adverse events and healthcare resource utilization.